<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Dendreon Starts Trial of Patients With Localized Prostate Cancer</title>
	<atom:link href="http://www.xconomy.com/seattle/2008/07/16/dendreon-starts-trial-of-patients-with-localized-prostate-cancer/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/seattle/2008/07/16/dendreon-starts-trial-of-patients-with-localized-prostate-cancer/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 11 Feb 2012 03:54:18 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.4</generator>
	<item>
		<title>By: IQWiG study finds considerable added benefit of abiraterone in prostate cancer &#8230; &#124; New Prostate Cancer Treatments</title>
		<link>http://www.xconomy.com/seattle/2008/07/16/dendreon-starts-trial-of-patients-with-localized-prostate-cancer/comment-page-1/#comment-555671</link>
		<dc:creator>IQWiG study finds considerable added benefit of abiraterone in prostate cancer &#8230; &#124; New Prostate Cancer Treatments</dc:creator>
		<pubDate>Sun, 08 Jan 2012 18:57:57 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=3413#comment-555671</guid>
		<description>[...] Dendreon Starts Trial of Patients With Localized Prostate Cancer Dendreon, the Seattle-based maker of immune-boosting therapies for cancer, said today it has started a mid-stage clinical trial of Provenge for patients with localized prostate cancer who are about to have their prostates surgically removed. &#8230; Read more on Xconomy [...]</description>
		<content:encoded><![CDATA[<p>[...] Dendreon Starts Trial of Patients With Localized Prostate Cancer Dendreon, the Seattle-based maker of immune-boosting therapies for cancer, said today it has started a mid-stage clinical trial of Provenge for patients with localized prostate cancer who are about to have their prostates surgically removed. … Read more on Xconomy [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>

